Press releases

ImmunoGenesis today announced the first patient has been dosed in the company’s Phase 1a/1b clinical trial of its lead candidate, IMGS-001, at The University of Texas MD Anderson Cancer Center in Houston, Texas. IMGS-001 is a dual-specific programmed cell death 1 ligand 1 (PD-L1)/programmed cell death 1 ligand 2 (PD-L2) antibody engineered with cytotoxic function designed to treat cold, immune-excluded tumors, which are resistant to existing immunotherapy.

ImmunoGenesis and Cancer Focus Fund, LP, announce that Cancer Focus Fund plans to invest $4.5 million to support the Phase 1a/1b clinical trial of ImmunoGenesis’ lead candidate, IMGS-001. The investment will support the portion of the IMGS-001 Phase 1a/1b multi-site clinical trial being conducted at MD Anderson. It coincides with ImmunoGenesis’ Series A financing, which is expected to close in the third quarter.

ImmunoGenesis announces that two poster presentations on its lead development program, IMGS-001, will be presented at the Society for Immunotherapy of Cancer 37th Annual Meeting (SITC 2022), November 8-12, 2022, in Boston, MA. The posters will be available on the ImmunoGenesis website following the conference.

ImmunoGenesis announces that President and CEO James Barlow will present on the company and its multiple immune-oncology therapeutic development programs targeting immune-excluded cold cancers at the upcoming 2022 BIO CEO & Investor Conference.

ImmunoGenesis announces that CEO James Barlow will present about the company and its multiple immune-oncology therapeutic development programs at Biotech Showcase 2022 on January 10 at 2:30 PM PST.

ImmunoGenesis announced the appointment of seasoned industry veteran Charles Schweizer, PhD, as Senior Vice President of Clinical Development. Dr. Schweizer delivers more than 25 years of oncology clinical product development, regulatory, and operations experience across pharma/biotech and contract research organizations.

ImmunoGenesis announces that preclinical data from its lead development programs were presented in six scientific posters at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021).

ImmunoGenesis announces the acceptance of six poster presentations on its lead development programs at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021).

•STING agonist can induce innate immune responses that allow the immune system to fight otherwise immunologically resistant cancers
•Phase 1 canine glioblastoma veterinary trial data show the promise of STING agonist as potential future therapy for human glioblastoma
•Data support the advancement of ImmunoGenesis’ STING-Immune Stimulating Antibody Conjugate (ISAC) in immunologically cold tumors

ImmunoGenesis announces the appointment of seasoned industry veterans to key roles to support the expansion of the company’s R&D, clinical and business development activities. ImmunoGenesis also announces the opening of a research laboratory in JLABS @ TMC to facilitate critical translational research for its drug development programs.